Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 13/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786269 | 0.94 | LDLR (1.00) | LDLRNPC1RAB9AKDM4EHPGD | |
| SCHEMBL6786897 | 0.93 | LDLR (0.98) | LDLRNPC1RAB9AKDM4EHPGD | |
| SCHEMBL6782591 | 0.89 | LDLR (0.82) | LDLRNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL6781245 | 0.88 | LDLR (1.00) | LDLRNPC1RAB9AKDM4EHPGD | |
| SCHEMBL6776926 | 0.85 | LDLR (0.82) | LDLRNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6778261 | 0.85 | LDLR (0.94) | LDLRNPC1RAB9AKDM4EHPGD | |
| SCHEMBL6679789 | 0.84 | LDLR (0.81) | LDLRKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6781226 | 0.83 | LDLR (0.84) | LDLRNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6682118 | 0.83 | LDLR (0.80) | LDLRNPC1RAB9AKDM4EHPGD | |
| SCHEMBL6488218 | 0.82 | LDLR (0.75) | LDLRNPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | claimed |
| JP-2001517620-A | — | — | 2001-10-09 | — | — | JP | claimed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | claimed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | claimed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | claimed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | claimed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | LDLR 2621/4885NPC1 1912/4885RAB9A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.